Table 2.
Prior treatments recorded at baseline
| Phase 1 | Phase 2 | All‐treated | ||
|---|---|---|---|---|
| 10 mg/kg QW/Q2W (n = 3) | 20 mg/kg QW/Q2W (n = 5) | 20 mg/kg QW/Q2W (n = 28) | 20 mg/kg QW/Q2W (n = 33) | |
| Median prior treatment lines (range) | 5.0 (4‐12) | 4.0 (3‐6) | 5.0 (2‐11) | 5.0 (2‐11) |
| Prior therapies, n (%) | ||||
| IMiD | 3 (100) | 5 (100) | 28 (100) | 33 (100) |
| Lenalidomide | 3 (100) | 5 (100) | 27 (96) | 32 (97) |
| Pomalidomide | 3 (100) | 3 (60) | 22 (79) | 25 (76) |
| Thalidomide | 1 (33) | 0 | 8 (29) | 8 (24) |
| PI | 3 (100) | 5 (100) | 28 (100) | 33 (100) |
| Bortezomib | 3 (100) | 5 (100) | 27 (96) | 32 (97) |
| Carfilzomib | 1 (33) | 2 (40) | 9 (32) | 11 (33) |
| Ixazomib | 0 | 1 (20) | 3 (11) | 4 (12) |
| Other | 1 (33) | 2 (40) | 10 (36) | 12 (36) |
| Panobinostat | 1 (33) | 1 (20) | 7 (25) | 8 (24) |
| Elotuzumab | 0 | 1 (20) | 6 (21) | 7 (21) |
| IMiD plus PI | 3 (100) | 5 (100) | 28 (100) | 33 (100) |
| Lenalidomide and bortezomib | 3 (100) | 5 (100) | 26 (93) | 31 (94) |
| Lenalidomide, bortezomib, pomalidomide and carfilzomib | 1 (33) | 1 (20) | 6 (21) | 7 (21) |
| Prior transplant | 2 (67) | 1 (20) | 9 (32) | 10 (30) |
| Patients refractory to prior therapies, n (%) | ||||
| Refractory to IMiD | 3 (100) | 5 (100) | 25 (89) | 30 (91) |
| Lenalidomide | 3 (100) | 5 (100) | 24 (86) | 29 (88) |
| Pomalidomide | 3 (100) | 3 (60) | 20 (71) | 23 (70) |
| Refractory to PI | 2 (67) | 4 (80) | 25 (89) | 29 (88) |
| Bortezomib | 2 (67) | 4 (80) | 20 (71) | 24 (73) |
| Carfilzomib | 1 (33) | 2 (40) | 8 (29) | 10 (30) |
| Ixazomib | 0 | 1 (20) | 3 (11) | 4 (12) |
| Refractory to IMiD and PI | 2 (67) | 4 (80) | 22 (79) | 26 (79) |
| Lenalidomide and bortezomib | 2 (67) | 4 (80) | 17 (61) | 21 (64) |
| Lenalidomide, bortezomib, pomalidomide and carfilzomib | 1 (33) | 1 (20) | 4 (14) | 5 (15) |
Abbreviations: IMiD, immunomodulatory drug; PI, proteasome inhibitor; Q2W, every 2 weeks; QW, every week.